- Home
- RGT vs NRXS Comparison
RGT vs NRXS Comparison
Compare RGT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RGT | NRXS |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RGT | NRXS |
|---|---|---|
| Price | $14.33 | $6.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 13.0K | ★ 139.8K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $132.54 |
| Revenue Next Year | N/A | $138.55 |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $12.01 | $2.21 |
| 52 Week High | $15.79 | $9.33 |
Technical Indicators
Market Signals| Indicator | RGT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 50.34 |
| Support Level | $13.97 | $6.51 |
| Resistance Level | $14.84 | $7.75 |
| Average True Range (ATR) | 0.19 | 0.50 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 25.35 | 20.69 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).